Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers / 부인종양

OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) when no more than two prior cytotoxic regimens have been used; due to concerns for gastrointestinal perforation. We sought to determine bevacizumab-related toxicities in heavily pretreated recurrent EOC. METHODS: We performed a retrospective chart review of patients with recurrent EOC, FTC, and PPC from 2001 to 2011. Patients who received at least two prior chemotherapy regimens before bevacizumab were included. Medical records were reviewed for bevacizumab associated toxicities. The Wilcoxon-Mann-Whitney test was used to compare quantitative variables. Survival was estimated with the Kaplan-Meier method. RESULTS: Sixty patients met inclusion criteria. At the start of bevacizumab treatment, the median age was 60 years and the median body mass index was 26.5 kg/m². More than 50% of patients received bevacizumab after three prior cytotoxic regimens. Grade 3 or higher bevacizumab associated toxicity events occurred in four patients, including one patient who developed a rectovaginal fistula. The median overall survival from the start of bevacizumab treatment was 21.05 months (95% CI, 18.23 to 32.67; range, 1.9 to 110 months). The number of cytotoxic regimens prior to bevacizumab treatment did not differ in those that experienced a toxicity versus those that did not (p=0.66). CONCLUSION: The use of bevacizumab in heavily pretreated EOC, FTC, or PPC is worth consideration.

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.

OBJECTIVE: To evaluate the adverse affects of paclitaxel and carboplatin combination chemotherapy. DESIGN: Descriptive cross sectional study MATERIAL AND METHOD: Patients with epithelial cancer of the ovary, fallopian tube and peritoneum treated with paclitaxel and carboplatin combination chemotherapy at Chiang Mai University Hospital between August 2003 and August 2004. RESULTS: Of 224 evaluable cycles in 63 patients treated with paclitaxel (175 mg/m2) and carboplatin (AUC 5), grade 3 and 4 neutropenia occurred in 37.1% or 41.3% of patients. 4.8% of patients experienced febrile neutropenia. Grade 3 and 4 leukopenia occurred in 8.6% of courses and 12.6% of patients. Grade 3 anemia occurred in 5.2% of courses and 9.5% of patients. Grade 3 thrombocytopenia occurred in 2.8% of courses and 9.6% of patients. The nonhematologic adverse affects were rare, however, some adverse events may be potentially life threatening. CONCLUSION: Adverse affects of paclitaxel and carboplatin combination chemotherapy are acceptable and manageable in the majority of patients.

Primary carcinoma of the fallopian tube in a 88 years old woman: review of the literature.

A woman of 88 years old with primary carcinoma of the fallopian tube, the oldest patient reported in the English literature according to the best of our knowledge, was presented. After debulking surgery four courses of chemotherapy including paclitaxel and carboplatin was performed. The patient was free of disease during two years follow-up.

Carcinoma de trompa de falopio: reporte de 7 casos / Fallopian tube carcinoma: report of 7 cases

Se resporta la experiencia de nuestro centro en el manejo del carcinoma primario de trompa de falopio tratados en el período entre 1985-1996. La sobrevida libre de enfermedad y total a 2 años fueron de 28,6 y 53,6 por ciento respectivamente. También se reporta una revisión de la literatura

Gestational choriocarcinoma of the fallopian tube--a case report.

Gestational Choriocarcinoma occurring in a female aged 20 years is being reported following ectopic tubal pregnancy. The case responded well to the conventional Chemotherapy regimen.

Adenocarcinoma Primario de Trompas de Falopio

El carcinoma primario de tormpas de falopio es el tumor menos frecuente del tracto genital femenino, con una incidencia que varía del 0.14 por ciento al 1.17 por ciento; la edad de presentación oscila entre 17 y 85 años con pico promedio en la quinta y sexta década de la vida; la principal vía de diseminación es la extensión directa. Los síntomas asociados tales como dolor, sangrado, flujo y sensación de masa son inespecíficos e incosistentes y como los métodos diagnósticos que se utilizan son poco sensibles y específicos se lleva al diagnóstico la mayoría de las veces por el estudio histopatológico de la pieza quirúrgica que se obtiene. El tratamiento incluye cirugía, radioterapia y quimioterapia; se obtienen mejores resultados cuando se utiliza Cis-platino como piedra angular del tratamiento

Role of radiotherapy in the management of primary carcinoma of the fallopian tube.

Primary fallopian tube carcinoma is a rare neoplasm. It may be postulated that postoperative loco-regional radiotherapy is a valuable adjunctive in the overall management of the tubal carcinoma. However, we can't advocate the efficacy of this approach authentically due to a very small number of cases. A prospective controlled and randomized trial with larger patient number may yield some definite conclusions regarding it's optimal management.